RxDoctor Payments Data

Danielle Craig

Family · Paris, TNNPI 1417321779

Payments from drug & device makers

$4,066in general payments, 2019–2025

Across 182 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Sumitomo Pharma America, Inc.$272
  • AbbVie$214
  • Boehringer Ingelheim$207
  • Daiichi Sankyo Inc.$195
  • Novo Nordisk$193
  • plus $2K from 32 others

What the payments were for

  • Travel & lodging$66416%
  • Food & beverage$3,40284%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,066 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron179$134,554
MyrbetriqMirabegron149$79,377
Solifenacin Succinate84$6,968
Tamsulosin Hcl330$4,729
Trimethoprim56$2,988
Estradiol30$2,105
Oxybutynin Chloride ErOxybutynin Chloride92$1,719
Finasteride92$996
Cephalexin142$928
Oxybutynin Chloride54$776
Fesoterodine Fumarate ErFesoterodine Fumarate16$710
NitrofurantoinNitrofurantoin Macrocrystal25$560
Testosterone Cypionate15$509
Cefdinir40$454
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$272$134,554179 claims
Astellas Pharma US IncMyrbetriq$30$79,377149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.

Other family in Paris

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →